NL-OMON28762尚未招募不适用
Effect of a single dose of 14.8 MBq/kg (0.4 mCi/kg) 90Y-ibritumomab tiuxetan (Zevalin”) following first-line R-CVP therapy in patients with follicular lymphoma on conversion rate assessed by FDG-PET and on stem cell mobilisation. A Phase II clinical trial.
Vumc, hematology department0 个研究点目标入组 31 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 31
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Histologically confirmed (according to WHO classification) CD 20 positive follicular lymphoma, grade 1, 2 or 3a, stage II, III or IV (with indication for treatment following local guidelines) of all FLIPI scores;
- •2. Age 18 years or older, for stem cell mobilisation analysis age 18-61 years;
排除标准
- •1. Any other anticancer treatment for NHL except the first line R-CVP;
- •2. Prolonged cytopenia during first line induction chemotherapy requiring more than 2 weeks delay due to insufficient bone marrow reserve;
研究者
相似试验
已完成
2 期
Effect of a single dose of 14.8 MBq/kg (0.4 mCi/kg) 90Y-ibritumomab tiuxetan (*Zevalin*) following first-line R-CVP therapy in patients with follicular lymphoma on conversion rate assessed by FDG-PET and on stem cell mobilisation. A Phase II clinical trial.NL-OMON33142Vrije Universiteit Medisch Centrum31
进行中（未招募）
不适用
Effect of a single dose of 14.8 MBq/kg (0.4 mCi/kg) 90Y-ibritumomab tiuxetan (Zevalin”) following first-line R-CVP therapy in patients with follicular lymphoma on conversion rate assessed by FDG-PET and on stem cell mobilisation. A Phase II clinical trial.follicular B cell NHLMedDRA version: 9.1Level: LLTClassification code 10024914Term: Low grade lymphomaMedDRA version: 9.1Level: LLTClassification code 10003899Term: B-cell lymphomaEUCTR2009-012944-17-NLVUMC
招募中
不适用
Efficacy and safety of a single dose of 14.8 MBq/kg (0.4 mCi/kg)90Y-ibritumomab tiuxetan (Zevalin) in elderly patients with diffuse large B-cell lymphoma and FDG-PET positive partial remission following first-line R-CHOP therapy. A Phase II clinical trial (HOVON 77).on-Hodgkin's lymphoma (NHL), B-Cell lymphomaNL-OMON22777Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) P/a HOVON Data CenterErasmus MC - Daniel den HoedPostbus 52013008 AE RotterdamTel: 010 7041560Fax: 010 7041028e-mail: hdc@erasmusmc.nl40
进行中（未招募）
不适用
Efficacy and safety of a single dose of 14.8 MBq/kg (0.4 mCi/kg)90Y-ibritumomab tiuxetan (Zevalin) in elderly patients with diffuse large B-cell lymphoma and FDG-PET positive partial remission following first-line R-CHOP therapy. A Phase II clinical trial (HOVON 77) - HOVON 77patients with diffuse Large B-Cell lymphoma, CD20-positiveMedDRA version: 8.1Level: LLTClassification code 10012820Term: Diffuse large B-cell lymphoma NOSEUCTR2005-003796-20-BEHOVON Foundation37
已完成
4 期
Effects of a 10 or 15 mg single intravenous bolus of ivabradine versus placebo on heart rate control during a multislice computed tomography coronary angiography for the evaluation of coronary artery diseaseMultislice computed tomography coronary angiography for the evaluation of coronary artery diseaseCirculatory SystemChronic ischaemic heart diseaseISRCTN67252793Institut de Recherches Internationales Servier (France)330